Biotech · Private company · San Francisco, CA, US
Shasqi, Inc.
Track this companyFree. Adds Shasqi, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- SQ3370Phase 2 · CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Phase 1/2a Study of SQ3370 in Patients With Advanced Solid TumorsPHASE1_PHASE2 · TERMINATED · started Aug 1, 2020ClinicalTrials.gov NCT04106492 · fetched Nov 12, 2026
NIH awards6
- CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistryFiscal year 2026 · $1.1MNIH RePORTER 5R44CA306491-02 · fetched Nov 12, 2026
- CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistryFiscal year 2025 · $1.1MNIH RePORTER 1R44CA306491-01 · fetched Nov 12, 2026
- Antigen-targeted activation of Topo1 inhibitors via click chemistryFiscal year 2025 · $431.9KNIH RePORTER 5R44CA291345-02 · fetched Nov 12, 2026
- Antigen-targeted activation of Topo1 inhibitors via click chemistryFiscal year 2024 · $1.6MNIH RePORTER 1R44CA291345-01A1 · fetched Nov 12, 2026
- Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcomaFiscal year 2024 · $322.1KNIH RePORTER 5R44CA265665-03 · fetched Nov 12, 2026
- Antibody-guided localized activation of bioorthogonal protodrugs via click chemistryFiscal year 2024 · $1.2MNIH RePORTER 5R44CA285160-02 · fetched Nov 12, 2026